交易中 10-06 10:34:03 美东时间
-0.235
-0.82%
As of Oct. 6, 2026, three stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices g...
今天 20:50
JP Morgan analyst Brian Ossenbeck upgrades RXO (NYSE:RXO) from Underweight to Neutral and raises the price target from $22 to $30.
今天 20:06
巴西总统选举首轮结果出炉!巴西概念股集体收高,XP升近31%领升;软件公司PTC升逾33%,获施耐德电气226亿美元收购;Vaxcyte升近31%,肺炎球菌疫苗传利好>>
今天 19:00
RXO shareholders will receive just $17.25 per share in cash and 0.0856 shares of C.H. Robinson Worldwide common stock for each RXO share, representing an implied total consideration of $30.2...
10-05 23:59
U.S. stocks were mixed, with the Dow Jones index falling over 250 points on Monday. Shares of RXO Inc (NYSE:RXO) rose sharply after C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) agreed to acquire the company in a cash-and-stock transaction with an implied value of $5.8 billion. Under the deal, RXO sha...
10-05 21:56
RXO, Inc. (NYSE:RXO) stock jumped nearly 23% during Monday’s premarket session after C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) agreed to acquire the company in a cash-and-stock transaction with an implied value of $5.8 billion. The transaction will create a combined company with an enterprise valu...
10-05 21:16
C.H. Robinson Worldwide, Inc. ("C.H. Robinson") (NASDAQ:CHRW) and RXO Inc. (NYSE:RXO) ("RXO"), a Fortune 1000 provider of asset-light tech-enabled transportation solutions, today announced that they have entered into a definitive agreement (the "Merger Agreement") under which C.H. Robinson will acqu...
10-05 19:04
今日重点评级关注:Leerink Partners:维持塞德斯医疗"跑赢大市"评级,目标价从70美元升至88美元;HC Wainwright & Co.:维持TriSalus Life Sciences"买入"评级,目标价从11美元升至12美元
09-24 16:10
Susquehanna analyst Harrison Bauer upgrades RXO (NYSE:RXO) from Negative to Neutral and lowers the price target from $20 to $19.
09-24 01:45
今日重点评级关注:康托·菲茨杰拉德:维持InflaRx"超配"评级,目标价从4美元升至6美元;RBC Capital:维持Nuvation Bio"跑赢大市"评级,目标价从19美元升至20美元
08-10 19:24